The future use of liraglutide: implications of the LEAD-2 study for treatment guidelines in type 2 diabetes

Prim Care Diabetes. 2010 Oct;4(3):139-44. doi: 10.1016/j.pcd.2010.03.003. Epub 2010 Apr 24.

Abstract

The effective identification and management of type 2 diabetes (T2D) in primary care is a healthcare priority. New antidiabetic agents, including glucagon-like peptide (GLP)-1 receptor agonists, may help overcome drawbacks with current treatments. These new agents have been reviewed in the updated National Institute for Health and Clinical Excellence (NICE) guidelines for the treatment of T2D. Liraglutide, a GLP-1 receptor agonist, was licensed for use in patients with T2D after the development of the NICE guidelines. Data from Phase III trials evaluating liraglutide are presented here in the context of the role of GLP-1 receptor agonists in NICE guidelines.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Clinical Trials, Phase III as Topic*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Europe
  • Evidence-Based Medicine
  • Glucagon-Like Peptide 1 / analogs & derivatives*
  • Glucagon-Like Peptide 1 / therapeutic use
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Liraglutide
  • Practice Guidelines as Topic*
  • Randomized Controlled Trials as Topic*
  • Societies, Medical
  • Treatment Outcome
  • United States

Substances

  • Hypoglycemic Agents
  • Liraglutide
  • Glucagon-Like Peptide 1